MELK and EZH2 Cooperate to Regulate Medulloblastoma Cancer Stem-like Cell Proliferation and Differentiation

Medulloblastoma is the most common malignant brain tumor in children. Although accumulated research has suggested that cancer stem-like cells play a key role in medulloblastoma tumorigenesis, the specific molecular mechanism regarding proliferation remains elusive. Here, we reported more abundant expression of maternal embryonic leucine-zipper kinase (MELK) and enhancer of zeste homolog 2 (EZH2) in medulloblastoma stem-like cells than in neural stem cells and the interaction between the two proteins could mediate the self-renewal of sonic hedgehog subtype medulloblastoma. In human medulloblastoma, extensive nodularity and large-cell/anaplastic subgroups differed according to the staining levels of MELK and EZH2 from the other two subgroups. The proportion of MELK- or EZH2-positive staining status could be considered as a potential indicator for survival. Mechanistically, MELK bound to and phosphorylated EZH2, and its methylation was induced by EZH2 in medulloblastoma, which could regulate the proliferation of cancer stem-like cells. In xenografts, loss of MELK or EZH2 attenuated medulloblastoma stem-like cell-derived tumor growth and promoted differentiation. These findings indicate that MELK-induced phosphorylation and EZH2-mediated methylation in MELK/EZH2 pathway are essential for medulloblastoma stem-like cell-derived tumor proliferation, thereby identifying a potential therapeutic strategy for these patients. Implications: This study demonstrates that the interaction occurring between MELK and EZH2 promotes self-proliferation and stemness, thus representing an attractive therapeutic target and potential candidate for diagnosis of medulloblastoma. Mol Cancer Res; 15(9); 1275–86. ©2017 AACR.

[1]  Yongmei Song,et al.  Differential expression of folate receptor 1 in medulloblastoma and the correlation with clinicopathological characters and target therapeutic potential , 2017, Oncotarget.

[2]  Shun-qian Jin,et al.  EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma–Induced Epigenetic Suppression of Osteoblast Differentiation , 2017, Molecular Cancer Research.

[3]  K. Hui,et al.  MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence. , 2016, Cancer letters.

[4]  D. Vetrie,et al.  Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition. , 2016, Cancer discovery.

[5]  B. Coyle,et al.  In vitro models of medulloblastoma: Choosing the right tool for the job. , 2016, Journal of biotechnology.

[6]  Kaitlyn M. Gayvert,et al.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. , 2016, Cancer cell.

[7]  S. Pfister,et al.  Nestin Mediates Hedgehog Pathway Tumorigenesis. , 2016, Cancer research.

[8]  M. Ewend,et al.  Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide. , 2016, Neuro-oncology.

[9]  A. Beitz,et al.  The relationship of bone-tumor-induced spinal cord astrocyte activation and aromatase expression to mechanical hyperalgesia and cold hypersensitivity in intact female and ovariectomized mice , 2016, Neuroscience.

[10]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[11]  Naoki Kagawa,et al.  Prognostic Value of Medulloblastoma Extent of Resection After Accounting for Molecular Subgroup: An Integrated Clinical and Molecular Analysis , 2016, The Lancet. Oncology.

[12]  Yusuke Nakamura,et al.  Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer , 2016, Oncotarget.

[13]  L. Ye,et al.  HBXIP and LSD1 Scaffolded by lncRNA Hotair Mediate Transcriptional Activation by c-Myc. , 2016, Cancer research.

[14]  F. Gilles,et al.  Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. , 2015, Neuro-oncology.

[15]  K. Bhat,et al.  EZH2 Protects Glioma Stem Cells from Radiation-Induced Cell Death in a MELK/FOXM1-Dependent Manner , 2015, Stem cell reports.

[16]  Li-xiang Xue,et al.  EZH2 Represses Target Genes through H3K27-Dependent and H3K27-Independent Mechanisms in Hepatocellular Carcinoma , 2014, Molecular Cancer Research.

[17]  Heather L. Mulder,et al.  The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes , 2014, Nature Communications.

[18]  David T. W. Jones,et al.  Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. , 2013, The Lancet. Oncology.

[19]  C. Burd,et al.  The Molecular Balancing Act of p16INK4a in Cancer and Aging , 2013, Molecular Cancer Research.

[20]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[21]  Bruno Di Stefano,et al.  Polycomb complexes in stem cells and embryonic development , 2013, Development.

[22]  D. Nam,et al.  Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. , 2013, Cancer cell.

[23]  Kaushal Joshi,et al.  Tumor‐Specific Activation of the C‐JUN/MELK Pathway Regulates Glioma Stem Cell Growth in a p53‐Dependent Manner , 2013, Stem cells.

[24]  Steven J. M. Jones,et al.  Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma , 2013, Acta Neuropathologica.

[25]  M. Loda,et al.  EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent , 2012, Science.

[26]  Yusuke Nakamura,et al.  Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer , 2012, Oncotarget.

[27]  Scott L. Pomeroy,et al.  Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.

[28]  P. Northcott,et al.  Targeting the enhancer of zeste homologue 2 in medulloblastoma , 2012, International journal of cancer.

[29]  R. Grossman,et al.  Medulloblastoma—Biology and Microenvironment: A Review , 2012, Pediatric hematology and oncology.

[30]  M. Kool,et al.  EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival , 2012, Clinical Cancer Research.

[31]  N. Smoll Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs) , 2012, Cancer.

[32]  H. Nakauchi,et al.  Serine/threonine kinase, Melk, regulates proliferation and glial differentiation of retinal progenitor cells , 2012, Cancer science.

[33]  P. Mischel,et al.  CD44v6 Regulates Growth of Brain Tumor Stem Cells Partially through the AKT-Mediated Pathway , 2011, PloS one.

[34]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[35]  Nicolò Riggi,et al.  EZH2 is essential for glioblastoma cancer stem cell maintenance. , 2009, Cancer research.

[36]  Carlos Caldas,et al.  Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer , 2009, Breast Cancer Research.

[37]  P. Febbo,et al.  Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. , 2009, Cancer cell.

[38]  C. Eberhart,et al.  Medulloblastoma stem cells. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Camargo,et al.  Maternal embryonic leucine zipper kinase transcript abundance correlates with malignancy grade in human astrocytomas , 2008, International journal of cancer.

[40]  Paul S Mischel,et al.  Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells , 2008, Journal of neuroscience research.

[41]  J. Hsieh,et al.  Down-regulation of Human DAB2IP Gene Expression Mediated by Polycomb Ezh2 Complex and Histone Deacetylase in Prostate Cancer* , 2005, Journal of Biological Chemistry.

[42]  Christoph Wülfing,et al.  Polycomb Group Protein Ezh2 Controls Actin Polymerization and Cell Signaling , 2005, Cell.

[43]  Renato Paro,et al.  Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. , 2004, Annual review of genetics.

[44]  A. Giordano,et al.  Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A , 2004, Oncogene.

[45]  Daniel H. Geschwind,et al.  Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[47]  Eric C. Holland,et al.  Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice , 2000, Nature Genetics.

[48]  H. Ha,et al.  Cloning and expression of a cDNA encoding a novel protein serine/threonine kinase predominantly expressed in hematopoietic cells. , 1997, Gene.

[49]  C. Nislow,et al.  Mammalian homologues of the Polycomb‐group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S.cerevisiae telomeres , 1997, The EMBO journal.

[50]  Jo Handelsman,et al.  EPIGENETIC REGULATION OF CELLULAR MEMORY BY THE POLYCOMB AND TRITHORAX GROUP PROTEINS , 2008 .